Intra-Spinal Transplantation Of Mesenchymal Stem Cell- Neural Progenitor (MSC-NP) In Patients With Amyotrophic Lateral Sclerosis (ALS) (S52.001)

OBJECTIVE:To evaluate safety of intraspinal transplantation of MSC-NP in patients with ALS and also to evaluate clinical response by determining ALS functional rating scale (ALS-FRS-R) and changing in the laboratory tests and imaging studies (MRI results BACKGROUND:ALS is a devastating incurable disease characterized by rapidly progressive weakness, muscle atrophy, fasciculations, spasticity, dysarthria, dysphagia, and dyspnea. Stem cell based therapies represent a new possible strategy for ALS treatment. The purpose of this study is to determine the efficacy and safety of intraspinal delivery of mesenchymal stem cells (MSCs) in ALS patients. METHODS: This is an interventional open label study, that 10 ALS patients were enrolled wirh specific inclusion and exclusion criteria. RESULTS and CONCLUSION:The preliminary results showed the MSCs are safe and the ALS-FRS-R will be changed in a stable condition. Study Supported by: Royan Institute Iran Disclosure: Dr. Shahbeigi has nothing to disclose. Dr. Hamediseresht has nothing to disclose. Dr. Aghadmi has nothing to disclose. Dr. Bakhshandepour has nothing to disclose. Dr. Najjari has nothing to disclose. Dr. Nejatollahi has nothing to disclose. Dr. Jalilzadeh has nothing to disclose. Dr. Samavati has nothing to disclose. Dr. Heydari has nothing to disclose. Dr. Orang has nothing to disclose. Dr. Noroozi has nothing to disclose.